<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927159</url>
  </required_header>
  <id_info>
    <org_study_id>IDRI-TBVPX-114</org_study_id>
    <nct_id>NCT01927159</nct_id>
  </id_info>
  <brief_title>Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDRI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aeras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South African Tuberculosis Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IDRI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and immunogenicity in&#xD;
      BCG-vaccinated healthy adult subjects of an investigational vaccine being developed for the&#xD;
      prevention of pulmonary tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>294 days</time_frame>
    <description>Solicited and unsolicited adverse events will be recorded for 28 days following each study injection; serious adverse events and adverse events of special interest will be recorded for the duration of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Days 0, 14, 42, 112, 126, 196, 294</time_frame>
    <description>Immunogenicity will be evaluated by measuring humoral and cellular responses to ID93 + GLA-SE at specified timepoints.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mcg ID93 + 2 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg ID93 + 2 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg ID93 + 5 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three intramuscular injections of saline at Days 0, 28, and 112.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ID93 + GLA-SE</intervention_name>
    <arm_group_label>10 mcg ID93 + 2 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_label>10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)</arm_group_label>
    <arm_group_label>10 mcg ID93 + 5 mcg GLA-SE Vaccine</arm_group_label>
    <arm_group_label>2 mcg ID93 + 2 mcg GLA-SE Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has completed the written informed consent process prior to start of screening&#xD;
             evaluations&#xD;
&#xD;
          2. Male or female who is ≥18 years and ≤50 years of age at the time of randomization&#xD;
&#xD;
          3. Agrees to stay in contact with the study site for the duration of the study, provide&#xD;
             updated contact information as necessary, and has no current plans to move from the&#xD;
             study area for the duration of the study&#xD;
&#xD;
          4. Agrees to avoid elective surgery for the full duration of the study&#xD;
&#xD;
          5. For female participants: agrees to avoid pregnancy from 21 days prior to Study Day 0&#xD;
             and for the full duration of the study. Women physically capable of pregnancy (not&#xD;
             sterilized and still menstruating or within 1 year of the last menses if menopausal)&#xD;
             in sexual relationships with men must use an acceptable method of avoiding pregnancy&#xD;
             during this period. Acceptable methods of avoiding pregnancy include a sterile sexual&#xD;
             partner, sexual abstinence(not engaging in sexual intercourse), hormonal&#xD;
             contraceptives (oral, injection, transdermal patch, or implant), vaginal ring,&#xD;
             intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide&#xD;
             gel&#xD;
&#xD;
          6. Has general good health, confirmed by medical history and physical examination&#xD;
&#xD;
          7. Has body mass index (BMI) between 19 and 33 (weight/height2) by nomogram&#xD;
&#xD;
          8. Had BCG vaccination at least 5 years ago, documented through medical history or&#xD;
             presence of scar&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute illness at the time of randomization&#xD;
&#xD;
          2. Oral temperature ≥37.5°C at the time of randomization&#xD;
&#xD;
          3. Clinically significant abnormal laboratory values for any of the following screening&#xD;
             laboratory parameters, per local laboratory normal ranges from blood collected within&#xD;
             30 days prior to Study Day 0 randomization as follows:&#xD;
&#xD;
               -  hemoglobin, hematocrit, absolute neutrophil count, absolute lymphocyte count, or&#xD;
                  platelet count below lower limit of normal (LLN)&#xD;
&#xD;
               -  white blood cell count above upper limit of normal (ULN) or below LLN (i.e., must&#xD;
                  be within normal limits)&#xD;
&#xD;
               -  ALT, AST, total bilirubin, alkaline phosphatase, creatinine, or blood urea&#xD;
                  nitrogen (BUN) above ULN&#xD;
&#xD;
          4. Evidence of systemic or local disease process on screening urinalysis&#xD;
&#xD;
          5. Evidence of significant active infection&#xD;
&#xD;
          6. History of treatment for active or latent tuberculosis or evidence of active&#xD;
             tuberculosis&#xD;
&#xD;
          7. Shared a residence within the last year prior to randomization with an individual on&#xD;
             anti-tuberculosis treatment or with culture or smear positive tuberculosis&#xD;
&#xD;
          8. History of autoimmune disease or immunosuppression&#xD;
&#xD;
          9. Used immunosuppressive medication within 42 days before randomization (inhaled and&#xD;
             topical corticosteroids are permitted)&#xD;
&#xD;
         10. Received immunoglobulin or blood products within 42 days before randomization&#xD;
&#xD;
         11. Received any investigational drug therapy or investigational vaccine within 182 days&#xD;
             before randomization, or planned participation in any other investigational study&#xD;
             during the study period&#xD;
&#xD;
         12. Received investigational Mtb vaccine at any time prior to randomization&#xD;
&#xD;
         13. Received a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
         14. Unable to discontinue current chronic prescription drug therapy that can be&#xD;
             hepatotoxic or toxic to the bone marrow or kidneys.&#xD;
&#xD;
         15. History or laboratory evidence of immunodeficiency state including but not limited to&#xD;
             any laboratory indication of HIV-1 infection&#xD;
&#xD;
         16. History of allergic disease or reactions (including allergy to kanamycin-related&#xD;
             antibiotics, allergic reaction to eggs, and severe eczema), likely to be exacerbated&#xD;
             by any component of the study vaccine&#xD;
&#xD;
         17. Previous medical history that may compromise the safety of the participant in the&#xD;
             study, including but not limited to: severe impairment of pulmonary function from&#xD;
             pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected&#xD;
             progressive neurological disease; or uncontrolled epilepsy&#xD;
&#xD;
         18. Evidence of chronic hepatitis (e.g., hepatitis B surface antigen or hepatitis C&#xD;
             antibody)&#xD;
&#xD;
         19. Chronic heavy ethanol intake which, in the opinion of the investigator, may compromise&#xD;
             the safety of the participant or interfere with the evaluation of the safety of the&#xD;
             vaccine&#xD;
&#xD;
         20. Cannabis smoking 3 or more days per week&#xD;
&#xD;
         21. Positive urine test for illicit drugs (opiates, cocaine, amphetamines)&#xD;
&#xD;
         22. History or evidence on physical examination of any systemic disease or any acute or&#xD;
             chronic illness that, in the opinion of the investigator, may interfere with the&#xD;
             evaluation of the safety or immunogenicity of the vaccine&#xD;
&#xD;
         23. All female participants: currently pregnant or lactating/nursing; or positive urine&#xD;
             pregnancy test during screening or on the day of study injection&#xD;
&#xD;
         24. Received a tuberculin skin test within 3 months (90 days) prior to Study Day 0&#xD;
&#xD;
         25. Any current medical, psychiatric, occupational, or substance abuse problems that, in&#xD;
             the opinion of the investigator, will make it unlikely that the participant will&#xD;
             comply with the protocol or may compromise the safety of the participant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Tameris, M.B.Ch.B.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SATVI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SATVI</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2013</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>TB</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 8, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT01927159/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

